Vascular Tissue Matrix Market Report 2026

The vascular tissue matrix market size has grown strongly in recent years. It will grow from $1.3 billion in 2025 to $1.41 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, expansion of reconstructive surgical procedures, advancements in biomaterial science, growth of regenerative medicine research, availability of tissue processing technologies.

The vascular tissue matrix market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising demand for vascular regeneration solutions, increasing investments in tissue engineering, expansion of personalized medicine approaches, growing use of advanced biomaterials, ongoing innovation in scaffold fabrication technologies. Major trends in the forecast period include increasing adoption of biologic vascular scaffolds, rising demand for regenerative cardiovascular therapies, growing use of decellularized tissue matrices, expansion of tissue engineering applications, enhanced focus on biocompatibility and long-term integration.

The increasing adoption of minimally invasive procedures is anticipated to drive the growth of the vascular tissue matrix market in the coming years. Minimally invasive procedures involve medical or surgical interventions performed through small or no incisions. Their growing popularity is attributed to benefits such as shorter recovery periods, reduced risk of complications, and lower postoperative pain when compared to conventional surgical approaches. Vascular tissue matrices are used in these procedures to support and regenerate blood vessels without requiring extensive surgical intervention. For example, in January 2024, Intuitive Surgical Inc., a US-based manufacturer of robotic surgical products, reported the placement of 415 da Vinci surgical systems in the fourth quarter of 2023, marking a 12% increase over 2022. As a result, the expanding use of minimally invasive procedures is contributing significantly to the growth of the vascular tissue matrix market.

Key players in the vascular tissue matrix market are increasingly concentrating on the development of innovative products, such as tissue matrices derived from the extracellular matrix (ECM) of the human umbilical cord, to strengthen their market position. A tissue matrix derived from human umbilical cord ECM consists of structural proteins and molecular components naturally present in the umbilical cord’s extracellular matrix, forming a supportive scaffold. For instance, in February 2024, StimLabs LLC, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its new wound care device, Corplex P. This product, the first graft developed from human umbilical cord ECM, is intended for the treatment of acute and chronic wounds. It includes connective tissue matrix elements such as collagens and glycosaminoglycans, including hyaluronic acid, which create a porous structure that supports cell infiltration and tissue regeneration. Corplex P is designed to manage a wide range of wounds, including partial- and full-thickness wounds, pressure ulcers, diabetic ulcers, surgical wounds, and trauma-related wounds.

In April 2023, Aziyo Biologics, a US-based regenerative medicine company with a commercial focus, entered into a partnership with LeMaitre Vascular Inc. to exclusively distribute its cardiovascular product portfolio in the United States. The partnership covers products developed using an extracellular matrix derived from porcine small intestine submucosa, which is intended to promote healing and reduce inflammation in surgical procedures. LeMaitre Vascular Inc., a US-based medical device company, offers vascular tissue matrix products as part of its broader cardiovascular product range.

Major companies operating in the vascular tissue matrix market are Abbott Laboratories, Medtronic PLC, Baxter International Inc., Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Getinge Group, Integra LifeSciences Corporation, Artivion Inc., CryoLife Inc., LeMaitre Vascular Inc., Cook Medical Inc., Humacyte Inc., BioCardia Inc., Organogenesis Holdings Inc., AxoGen Inc., Collagen Matrix Inc., ACell Inc., Reva Medical Inc.

North America was the largest region in the vascular tissue matrix market in 2025. The regions covered in the vascular tissue matrix market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vascular tissue matrix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the vascular tissue matrix market by increasing costs of imported biomaterials, processing equipment, sterilization systems, and advanced polymers used in matrix fabrication. Hospitals and research centers in North America and Europe are most affected due to reliance on imported biomaterial inputs, while Asia-Pacific faces higher costs for export-oriented scaffold production. These tariffs are increasing product pricing and development costs. However, they are also encouraging domestic biomaterial sourcing, regional manufacturing of tissue matrices, and investment in local regenerative medicine supply chains.

The vascular tissue matrix market research report is one of a series of new reports that provides vascular tissue matrix market statistics, including vascular tissue matrix industry global market size, regional shares, competitors with a vascular tissue matrix market share, detailed vascular tissue matrix market segments, market trends and opportunities, and any further data you may need to thrive in the vascular tissue matrix industry. This vascular tissue matrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A vascular tissue matrix is a biomaterial scaffold engineered to aid the growth, repair, or regeneration of vascular tissues, including arteries, veins, and capillaries. It offers a three-dimensional support structure that closely resembles the natural extracellular matrix (ECM) of vascular tissues, enabling effective cell attachment, proliferation, and differentiation.

The primary types of vascular tissue matrix include biologic matrix and synthetic matrix. A biologic matrix is derived from natural tissues and cells, usually sourced from human or animal origins. These matrices are applied in medical procedures to repair or replace damaged tissues, supporting natural healing through integration with the body’s own tissues. This matrix is utilized across multiple therapeutic areas such as orthopedics, dermatology, cardiology, neurology, oncology, and others, with applications in hospitals, clinics, and additional healthcare settings.

The vascular tissue matrix market consists of sales of wound care devices, stent grafts, vascular filters, and synthetic vascular grafts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.